FY2025 EPS Estimates for ADMA Biologics Boosted by Analyst

ADMA Biologics, Inc. (NASDAQ:ADMA) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for shares of ADMA Biologics in a note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings per share of $0.73 for the year, up from their previous forecast of $0.70. Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA Biologics Stock Up 0.8 %

Shares of ADMA stock opened at $19.80 on Friday. The company has a market capitalization of $4.68 billion, a price-to-earnings ratio of 70.71 and a beta of 0.60. ADMA Biologics has a one year low of $5.90 and a one year high of $23.64. The company’s fifty day moving average price is $16.76 and its 200-day moving average price is $18.04. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Hedge Funds Weigh In On ADMA Biologics

Several institutional investors have recently bought and sold shares of ADMA. Larson Financial Group LLC purchased a new position in ADMA Biologics during the third quarter valued at $31,000. GAMMA Investing LLC grew its stake in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares in the last quarter. National Bank of Canada FI purchased a new position in shares of ADMA Biologics in the 3rd quarter worth $35,000. Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics in the 4th quarter worth $35,000. Finally, Vision Financial Markets LLC purchased a new position in shares of ADMA Biologics in the 4th quarter worth $51,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.